GENE THERAPY TECHNOLOGY Sample Clauses

GENE THERAPY TECHNOLOGY. Notwithstanding Section 7.1.1 above, GenVec shall own all inventions and intellectual property made in connection with this Agreement during the term of this Agreement (i) solely by GenVec employees or agents or jointly by employees or agents of Fuso and GenVec that relate to the introduction of genetic material of nucleic acid composition, or a portion thereof, into a vector and/or cell to create a desired effect or identify an unknown effect, including techniques and processes relating to the manufacture, evaluation and use thereof, and methods relating to all of the foregoing, (ii) by either or both of the parties and/or their agents that relate to or are made using materials transferred to Fuso by or on behalf of GenVec, or (iii) by either or both of the parties and/or their agents that relate to or are made using Collaboration Products, * Vector, * Vector, *-TNF Vector or * Vector (collectively, "Gene Therapy Technology"). Fuso hereby assigns to GenVec all its right, title and interest it may otherwise hold in or to such Gene Therapy Technology and any patent applications or patents relating thereto. Fuso shall, at the request of GenVec, execute, and deliver or cause to be delivered, all such consents, documents or further instruments of assignment or transfer, and take or cause to be taken all such actions GenVec reasonably deems necessary or desirable in order for GenVec to obtain the full benefits of the assignment herein.
Sample 1Sample 2See All (4)
AutoNDA by SimpleDocs
GENE THERAPY TECHNOLOGY. In the event that Fuso desires to acquire a license under Gene Therapy Technology for commercial applications in the Territory, Fuso shall notify GenVec, and the parties agree to negotiate in good faith for a period of ninety (90) days, or such longer period as the parties may agree, the terms and conditions on which GenVec would grant such a license to Fuso; provided, however, in no event shall GenVec be obligated to negotiate or grant a license for any commercial application(s) which might compete with the business interests of GenVec or its Affiliates.
Sample 1Sample 2
GENE THERAPY TECHNOLOGY. In the event that Fuso desires to *, Fuso shall notify GenVec, and the parties agree to negotiate in good faith for a period of *, or such longer period as the parties may agree, the terms and conditions on which GenVec would grant such a license to Fuso; provided, however, in no event shall GenVec be obligated to negotiate or grant a license for any * which might compete with *.
Sample 1Sample 2
GENE THERAPY TECHNOLOGY. Notwithstanding Section 7.1.1 above, Title to all inventions and intellectual property which relates to Gene Therapy made solely by GenVec employees or its agents (including researchers at DFCI) or jointly by employees or the agents of Fuso and GenVec in connection with the Research Program (in each case, "Gene Therapy Technology") shall be owned by GenVec. Fuso hereby assigns to GenVec all its right, title and interest it may otherwise hold in or to such Gene Therapy Technology and any patent applications or patents relating thereto. Fuso shall, at the request of GenVec, execute, and deliver or cause to be delivered, all such consents, documents or further instruments of assignment or transfer, and take or cause to be taken all such actions GenVec reasonably deems necessary or desirable in order for GenVec to obtain the full benefits of the assignment herein.
Sample 1

Related to GENE THERAPY TECHNOLOGY

  • New Technology When new or updated technology is introduced into a workplace, it will be the responsibility of the employer to provide appropriate and, if necessary, ongoing training to the employees directly affected. Such training will include any health and safety implications or information that will enable employees to operate the equipment without discomfort and will help maintain their general well-being.

  • Technology Discoveries, innovations, Know-How and inventions, whether patentable or not, including computer software, recognized under U.S. law as intellectual creations to which rights of ownership accrue, including, but not limited to, patents, trade secrets, maskworks and copyrights developed under this Agreement.

  • Background Technology List here prior contracts to assign Inventions that are now in existence between any other person or entity and you. [ ] List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse side if necessary.

  • Licensed Technology The term “Licensed Technology” shall mean the Licensed Patent Rights, Licensed Know-How and Licensed Biological Materials.

  • Third Party Technology Customer is hereby notified that third parties have licensed certain technology to Company, which is contained in the Software. Notwithstanding anything herein to the contrary, Customer hereby consents to the disclosure of Customer’s identity, and such other terms of this Agreement as necessary, to such third party licensors for the purpose of enabling Company to comply with the terms and conditions of such third party licenses. Any such Customer information will be provided pursuant to an obligation of confidentiality and nondisclosure at least as stringent as that imposed by this Agreement.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Technology License 4.1 Unless any event described in Article 2.2 or 2.3 of this Agreement occurs, all of the technology required to be licensed for any of Party B’s business shall be provided by Party A on an exclusive basis. Party A will try its best to license Party B to use the technology owned by Party A, or re-license Party B to use the technology as approved by the owner.

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

Time is Money Join Law Insider Premium to draft better contracts faster.